Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 2, 2015, Pages 1878-1888

  Zeng, Wen ^a   Sun, Hanying ^a   Meng, Fankai ^a   Liu, Zeming ^a   Xiong, Jing ^a   Zhou, Sheng ^a   Li, Fan ^a   Hu, Jia ^a   Hu, Zhiquan ^a   Liu, Zheng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

C MYC; ERG; Immunohistochemistry; Prostate cancer; TMPRSS2 ERG

Indexed keywords

ERG PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; ONCOPROTEIN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ERG; TUMOR MARKER;

AGED; CANCER GRADING; CANCER STAGING; CELL NUCLEUS; CHEMISTRY; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL NUCLEUS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG;

EID: 84928111552     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD and Pollack JR. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67: 8504-8510.
2. Sato H, Minei S, Hachiya T, Yoshida T and Takimoto Y. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients. Int J Urol 2006; 13: 761-766.
3. Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, Cathelineau X and Cussenot O. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Hum Pathol 2013; 44: 1617-1623.
4. Bova GS and Isaacs WB. Review of allelic loss and gain in prostate cancer. World J Urol 1996; 14: 338-346.
5. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB and Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51.
6. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M and Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790-2799.
7. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S and Petrovics G. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010; 13: 311-315.
8. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J and De Marzo AM. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21: 1156-1167.
9. Yang G, Timme TL, Frolov A, Wheeler TM and Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 2005; 103: 1186-1194.
10. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM and Eisenberger MA. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012; 118: 6063-6071.
11. Reis ST, Timoszczuk LS, Pontes-Junior J, Viana N, Silva IA, Dip N, Srougi M and Leite KR. The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer. Clinics (Sao Paulo) 2013; 68: 652-657.
12. Samaratunga H and Epstein JI. What is the molecular pathology of low-risk prostate cancer? World J Urol 2008; 26: 431-436.
13. Jenkins RB, Qian J, Lieber MM and Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57: 524-531.
14. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M and Mucci LA. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012; 21: 1497-1509.
15. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT and Nelson PS. Urinary TMPRSS2: ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013; 19: 2442-2450.
16. Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L and Ruiz C. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 126-131.
17. Berg KD, Vainer B, Thomsen FB, Roder MA, Gerds TA, Toft BG, Brasso K and Iversen P. ERG Protein Expression in Diagnostic Specimens Is Associated with Increased Risk of Progression During Active Surveillance for Prostate Cancer. Eur Urol 2014.
18. Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S and Sesterhenn I. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 2011; 35: 432-441.
19. Rahim S and Uren A. Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. Am J Transl Res 2013; 5: 254-268.
20. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG and Srivastava S. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-5353.
21. Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jeronimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA and Teixeira MR. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer 2012; 51: 240-249.
22. Liman N, Alan E, Bayram GK and Gurbulak K. Expression of survivin, Bcl-2 and Bax proteins in the domestic cat (Felis catus) endometrium during the oestrus cycle. Reprod Domest Anim 2013; 48: 33-45.
23. Zeng W, Meng F, Liu Z, Mao X, Luo L, Zheng M, Qin S, Liu W, Zhou J, Sun H and Huang L. Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. Int J Clin Exp Pathol 2014; 7: 4239-4246.
24. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM and Kunju LP. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med 2012; 136: 935-946.
25. Zhang Y, Perez T, Blondin B, Du J, Liu P, Escarzaga D, Coon JS, Morrison LE and Pestova K. Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment. BMC Cancer 2014; 14: 129.
26. Trudel D, Zafarana G, Sykes J, Have CL, Bristow RG and van der Kwast T. 4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. J Histochem Cytochem 2013; 61: 500-509.
27. Barros-Silva JD, Ribeiro FR, Rodrigues A, Cruz R, Martins AT, Jeronimo C, Henrique R and Teixeira MR. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes Cancer 2011; 50: 662-671.
28. Ribeiro FR, Paulo P, Costa VL, Barros-Silva JD, Ramalho-Carvalho J, Jeronimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA and Teixeira MR. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One 2011; 6: e22317.
29. Fernandez-Serra A, Rubio L, Calatrava A, Rubio-Briones J, Salgado R, Gil-Benso R, Espinet B, Garcia-Casado Z and Lopez-Guerrero JA. Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR. Biomed Res Int 2013; 2013: 465179.
30. FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL and Huntsman DG. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008; 8: 230.